BioVie to present Phase 2 bezisterim Long COVID trial results at ANA 2026 meeting
BioVie flagged new Phase 2 findings for bezisterim in Long COVID, set for poster presentation at ANA2026 on Oct. 18. The company also plans to present initial Phase 2 results for bezisterim in early Parkinson’s disease at the same meeting on Oct. 19. Both readouts focus on efficacy and safety observations, with disclos